S1 strategy.

Detailed search strategy for PubMed

- 1. Retinopathy of Prematurity[MeSH]
- 2. Prematurity Retinopath*[Tiab] OR Retrolental Fibroplasia*[Tiab]OR

Fibroplasia* Retrolental[Tiab]

- 3.1 OR 2
- 4. Anti-VEGF[MeSH]
- 5. Mvasi[Tiab] OR Avastin[Tiab] OR Ranibizumab[Tiab] OR aflibercept[Tiab]
- OR Anti-vascular endothelial growth factor[Tiab]

6.4 OR 5

- 7. Error*,Refractive[MeSH]
- 8. Error*, Refractive [Tiab] OR Refractive Error* [Tiab] OR

Disorder*,Refractive[Tiab] OR Ametropia[Tiab]

- 9.7 OR 8
- 10 3 AND 6 AND 9

S2 forest plot : Forest plot of the effect of different anti-VEGF drugs on spherical equivalent.

	A	nti-VEGF	-	Laser				Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
1.1.1 bevacizumab										
chen 2020	-0.16	2	25	-3.49	4.39	22	6.3%	3.33 [1.34, 5.32]	│ _ • _	
Geloneck 2014 zone1	-1.51	3.42	52	-8.44	7.57	35	5.0%	6.93 [4.26, 9.60]		
Geloneck2014 zone2	-0.58	2.53	58	-5.83	5.87	66	7.2%	5.25 [3.69, 6.81]		
Gunay 2017(1)	-0.57	3.24	107	-0.81	5.35	113	8.0%	0.24 [-0.92, 1.40]	-+	
harder 2013	-1.04	4.24	23	-4.41	5.5	26	4.9%	3.37 [0.64, 6.10]	— • — •	
Hwang 2015	-2.4	3.5	22	-5.3	5.4	32	5.5%	2.90 [0.53, 5.27]		
Issac 2015	-3.57	6.19	23	-6.39	4.41	22	4.3%	2.82 [-0.31, 5.95]	+	
Kabatas 2016(1)	-1.49	3.04	24	-1.27	2.8	72	7.6%	-0.22 [-1.60, 1.16]		
Kuo 2015	-1.53	2.2	15	-1.71	1.27	14	7.8%	0.18 [-1.12, 1.48]	-+	
Lee 2018	-0.1	3.3	33	-2.5	4.2	24	6.2%	2.40 [0.38, 4.42]		
O'Keeffe 2016	-0.9	2.66	15	-2.73	3.83	15	5.6%	1.83 [-0.53, 4.19]	+	
Roohipoor 2018	-1.26	3.19	397	-2.84	2.77	190	9.1%	1.58 [1.08, 2.08]		
Vujanović 2017	-0.5	2.908	42	-0.2	5.19	90	7.6%	-0.30 [-1.69, 1.09]		
Subtotal (95% CI)			836			721	85.1%	2.10 [1.10, 3.11]	•	
Heterogeneity: Tau ² = 2	.47; Chi ^a	= 66.92	2, df = 1	2 (P < 0).0000 [.]	1); l² = 3	82%			
Test for overall effect: Z	= 4.11 (F	° < 0.00	01)							
1.1.2 ranibizumab										
Gunay 2017(2)	0.78	1.93	44	-0.81	5.35	113	8.1%	1.59 [0.45, 2.73]		
<abatas2016(2)< td=""><td>-1.79</td><td>2.87</td><td>12</td><td>-1.27</td><td>2.8</td><td>72</td><td>6.8%</td><td>-0.52 [-2.27, 1.23]</td><td></td></abatas2016(2)<>	-1.79	2.87	12	-1.27	2.8	72	6.8%	-0.52 [-2.27, 1.23]		
Subtotal (95% CI)			56			185	14.9%	0.64 [1.41, 2.70]		
Heterogeneity: Tau ² = 1	.66; Chi ^a	= 3.93,	df = 1 (P = 0.0	5); I ² =	75%				
Test for overall effect: Z	= 0.61 (F	P = 0.54)							
Total (95% CI)			892			906	100.0%	1.86 [0.99, 2.74]	•	
Heterogeneity: Tau ² = 2	.14; Chi⁼	= 72.15	5. df = 1	4 (P < 0).0000 [.]	1);	B1%			
Test for overall effect: Z									-10 -5 0 5 1	
to fair a sub-second state -									Laser Anti-VEGF	

Test for subaroup differences: Chi² = 1.57. df = 1 (P = 0.21). l² = 36.1%


S3 forest plot : Forest plot of the influence of different follow-up time on spherical equivalent.

	Anti-VEGF			Laser				Mean Difference	Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	
1.2.1 ≤2 year										
Gunay 2017(1)	-0.57	3.24	107	-0.81	5.35	113	8.5%	0.24 [-0.92, 1.40]	-+	
Gunay 2017(2)	0.78	1.93	44	-0.81	5.35	113	8.6%	1.59 [0.45, 2.73]		
harder 2013	-1.04	4.24	23	-4.41	5.5	26	5.2%	3.37 [0.64, 6.10]	—	
Hwang 2015	-2.4	3.5	22	-5.3	5.4	32	5.9%	2.90 [0.53, 5.27]		
Issac 2015	-3.57	6.19	23	-6.39	4.41	22	4.5%	2.82 [-0.31, 5.95]	+	
Kabatas 2016(1)	-1.49	3.04	24	-1.27	2.8	72	8.1%	-0.22 [-1.60, 1.16]		
Kabatas2016(2)	-1.79	2.87	12	-1.27	2.8	72	7.2%	-0.52 [-2.27, 1.23]		
Roohipoor 2018	-1.26	3.19	397	-2.84	2.77	190	9.6%	1.58 [1.08, 2.08]	+	
Vujanović 2017	-0.5	2.908	42	-0.2	5.19	90	8.0%	-0.30 [-1.69, 1.09]		
Subtotal (95% CI)			694			730	65.7%	0.98 [0.19, 1.77]	◆	
Heterogeneity: Tau ² = 0	.80; Chi²	= 22.94	l, df = 8	(P = 0.1)	003); P	² = 65%				
Test for overall effect: Z	= 2.43 (F	P = 0.01)							
1.2.2 > 2 year										
Geloneck 2014 zone1	-1.51	3.42	52	-8.44	7.57	35	5.3%	6.93 [4.26, 9.60]		
Geloneck2014 zone2	-0.58	2.53	58	-5.83	5.87	66	7.7%	5.25 [3.69, 6.81]		
kang 2019 zone1	-1.22	2.63	4	-2.69	3.27	2	2.3%	1.47 [-3.74, 6.68]		
kang2019 zone2	-0.32	5.51	18	-1	3.52	28	5.0%	0.68 [-2.18, 3.54]		
Kuo 2015	-1.53	2.2	15	-1.71	1.27	14	8.2%	0.18 [-1.12, 1.48]		
O'Keeffe 2016	-0.9	2.66	15	-2.73	3.83	15	5.9%	1.83 [-0.53, 4.19]		
Subtotal (95% CI)			162			160	34.3%	2.79 [0.32, 5.25]		
Heterogeneity: Tau ² = 7	.62; Chi ²	= 36.80), df = 5	(P < 0.)	00001)); I ² = 8I	5%			
Test for overall effect: Z	= 2.22 (F	P = 0.03)							
Total (95% CI)			856			890	100.0%	1.66 [0.76, 2.56]	◆	
Heterogeneity: Tau ² = 2	11: Chi²	= 68 09	df = 1	4 (P ≤ f	0000	1);	79%	. ,	+ + + +	
Test for overall effect: Z									-10 -5 0 5 10	
Test for subaroup differ				1 (P = 1	0.17)	² = 46.6	96		Laser Anti-VEGF	

Test for subaroup differences: Chi² = 1.87. df = 1 (P = 0.17). l^2 = 46.6%

S4 forest plot :Forest plot of lens thickness (LT).

	AN	TI-VEC	GF	L	ASER			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% Cl	IV. Random, 95% Cl
chen2019	3.5	0.16	25	3.75	0.16	22	51.2%	-0.25 [-0.34, -0.16]	*
vujanovic2017	4.34	0.66	42	3.96	0.32	90	48.8%	0.38 [0.17, 0.59]	
Total (95% CI)			67			112	100.0%	0.06 [-0.56, 0.67]	
Heterogeneity: Tau ² =	0.19; Cl	hi² = 28	3.98, df	= 1 (P	< 0.00	001); l ²	= 97%		
Test for overall effect: Z = 0.18 (P = 0.85)									-1 -0.5 0 0.5 1 ANTI-VEGF LASER



S5 funnel plot: Publication bias was evaluated by the funnel plot.